Landos Biopharma To Present New Data On Immunometabolism At The 19th Annual Congress Of The European Crohn's And Colitis Organisation
Portfolio Pulse from Benzinga Newsdesk
Landos Biopharma, Inc. (NASDAQ:LABP) announced that six abstracts on immunometabolism for autoimmune diseases will be presented at the ECCO congress in February 2024. The data includes studies on novel agonists NX-13 and LABP-69, with NX-13 currently in a Phase 2 trial for ulcerative colitis. Topline results are expected in Q4 2024.

January 08, 2024 | 1:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Landos Biopharma will present new data on immunometabolism at ECCO, including studies on NX-13, which is in a Phase 2 trial for UC with results expected in Q4 2024.
The announcement of Landos Biopharma presenting new data at a major congress is likely to be viewed positively by investors, as it demonstrates progress in the company's research and development efforts. The focus on NX-13, which is in a Phase 2 trial, could raise expectations for the drug's potential, possibly leading to increased investor interest and a positive short-term impact on the stock price. However, the actual impact will depend on the market's perception of the presented data and the overall progress of the clinical trial.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100